Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue

Rapid in situ determination of surgical resection margins during breast cancer surgery would reduce patient time under anesthesia. We present preliminary data supporting the use of a fluorescent glucose analog (2-NBDG) as an optical contrast agent to differentiate freshly excised breast tissue containing cancerous cells from normal breast tissue. Multi-spectral images of 14 breast cancer specimens acquired before and after incubation with 2-NBDG demonstrated increased fluorescent signal in all of the malignant tissue due to increased 2-NBDG consumption. We demonstrate that 2-NBDG has potential as an optical contrast agent to differentiate cancerous from non-cancerous tissue.

[1]  C. Perez Conservation Therapy in T1‐T2 Breast Cancer: Past, Current Issues, and Future Challenges and Opportunities , 2003, Cancer journal.

[2]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[4]  G. Hortobagyi,et al.  Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.

[5]  Timothy J. Muldoon,et al.  Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy‐glucose , 2009, International journal of cancer.

[6]  D. Schultz,et al.  Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience. , 1999, International journal of radiation oncology, biology, physics.

[7]  E. McDermott,et al.  Positron emission tomography in the staging and management of breast cancer , 2004, The British journal of surgery.

[8]  R L Wahl,et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Weber,et al.  Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. , 1955, Cancer research.

[10]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[12]  Hideaki Matsuoka,et al.  Measurement of Glucose Uptake and Intracellular Calcium Concentration in Single, Living Pancreatic β-Cells* , 2000, The Journal of Biological Chemistry.

[13]  F. Penault-Llorca,et al.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.

[14]  R L Wahl,et al.  An Immunohistochemical Study , 2006 .

[15]  R. Drezek,et al.  Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy , 2010, Breast Cancer Research and Treatment.

[16]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[17]  S. Singletary,et al.  Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy , 2007, Annals of Surgical Oncology.

[18]  Alberto Luini,et al.  The surgical margin status after breast-conserving surgery: discussion of an open issue , 2008, Breast Cancer Research and Treatment.

[19]  J. Gazet,et al.  The importance of the resection margin in conservative surgery for breast cancer. , 1996, European Journal of Surgical Oncology.

[20]  George,et al.  Glucose-6-phosphatase Activity in Normal, Precancerous, and Neoplastic Tissues* , 2006 .

[21]  J. Mackey,et al.  The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer , 2009, Current oncology.

[22]  R. Weichselbaum,et al.  Breast preservation in stage I and II carcinoma of the breast: The University of Chicago experience , 1996 .

[23]  S. Jeffrey,et al.  Predictors of reexcision findings and recurrence after breast conservation. , 2003, International journal of radiation oncology, biology, physics.

[24]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Nizar Mullani,et al.  Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells , 2005, Molecular Imaging and Biology.

[26]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[27]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[28]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Chandramouli,et al.  Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. , 2006, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[30]  J. Vilcoq,et al.  Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. , 1989, International journal of radiation oncology, biology, physics.

[31]  M E Phelps,et al.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.

[32]  L. Adler,et al.  Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. , 1997, Radiology.